Current therapeutics and practical management strategies for pulmonary arterial hypertension

American Heart Journal

Volumn 162, Issue 2, 2011, Pages 201-213

  Agarwal, Richa ^a   Gomberg Maitland, Mardi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMLODIPINE; BOSENTAN; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; IMATINIB; NIFEDIPINE; NILOTINIB; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPOSTINIL; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LONG TERM CARE; LUNG HEMODYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; THERAPY; VASODILATATION;

EID: 80051671703     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.05.012     Document Type: Review

References (80)

1. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension: results from a national prospective registry Ann Intern Med 115 1991 343 349
2. M. Humbert, O. Sitbon, and A. Yaici Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 36 2010 549 555
3. T. Thenappan, S.J. Shah, and S. Rich Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation Eur Respir J 35 2010 1079 1087
4. R.J. Barst, J.S. Gibbs, and H.A. Ghofrani Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S78 84
5. M. Gomberg-Maitland, C. Dufton, and R.J. Oudiz Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective J Am Coll Cardiol 57 2011 1053 1061
6. V.V. McLaughlin, S.L. Archer, and D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation 119 2009 2250 2294
7. M.R. Fisher, P.R. Forfia, and E. Chamera Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension Am J Respir Crit Care Med 179 2009 615 621
8. J.D. Rich, S.J. Shah, and R. Swamy The inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice Chest 139 2011 988 993
9. L.G. Rudski, W.W. Lai, and J. Afilalo Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography J Am Soc Echocardiogr 23 2010 685 713 [quiz 86-8]
10. S.B. Eysmann, H.I. Palevsky, and N. Reichek Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension Circulation 80 1989 353 360 (Pubitemid 19195745)
11. N. Galie, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Respir J 34 2009 1219 1263
12. W.M. Bradlow, R. Assomull, and P.J. Kilner Understanding late gadolinium enhancement in pulmonary hypertension Circ Cardiovasc Imaging 3 2010 501 503
13. J. Marcus, A. Noordegraaf, and R. Roeleveld Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension. Noninvasive monitoring using MRI Chest 119 2001 1761 1765 (Pubitemid 32744934)
14. R. Paz, R.H. Mohiaddin, and D.B. Longmore Magnetic resonance assessment of the pulmonary arterial trunk anatomy, flow, pulsatility and distensibility Eur Heart J 14 1993 1524 1530 (Pubitemid 24002717)
15. A.A. Tardivon, E. Mousseaux, and F. Brenot Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging Am J Respir Crit Care Med 150 1994 1075 1080 (Pubitemid 24318038)
16. K.G. Blyth, B.A. Groenning, and T.N. Martin Contrast enhanced- cardiovascular magnetic resonance imaging in patients with pulmonary hypertension Eur Heart J 26 2005 1993 1999 (Pubitemid 41435724)
17. V.V. McLaughlin, D.B. Badesch, and M. Delcroix End points and clinical trial design in pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S97 107
18. S. Rich, E. Kaufman, and P. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 1992 76
19. O. Sitbon, M. Humbert, and X. Jais Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111 (Pubitemid 40847788)
20. N. Galie, A. Manes, and L. Negro A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403
21. S. Rich, M. Seidlitz, and E. Dodin The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension Chest 114 1998 787 792 (Pubitemid 28433741)
22. S.R. Johnson, S. Mehta, and J.T. Granton Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review Eur Respir J 28 2006 999 1004 (Pubitemid 46331971)
23. M. Cohen, W.D. Edwards, and V. Fuster Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy J Am Coll Cardiol 7 1986 172 175 (Pubitemid 16132473)
24. L.J. Rubin, B.M. Groves, and J.T. Reeves Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension Circulation 66 1982 334 338 (Pubitemid 12084983)
25. R. Barst, L. Rubin, and W. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301 (Pubitemid 26033085)
26. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
27. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788 (Pubitemid 34925627)
28. D. Badesch, V. Tapson, and M. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease Ann Intern Med 132 2000 425 434 (Pubitemid 30149039)
29. H. Nunes, M. Humbert, and O. Sitbon Prognositc factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension Am J Respir Crit Care Med 167 2003 1433 1439 (Pubitemid 36609730)
30. M.J. Krowka Evolving dilemmas and management of portopulmonary hypertension Semin Liver Dis 26 2006 265 272 (Pubitemid 44141934)
31. R.M. Califf, K.F. Adams, and W.J. McKenna A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) Am Heart J 134 1997 44 54 (Pubitemid 27329022)
32. A. Doran, D. Ivy, and R. Barst Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension Int J Clin Pract 62 2008 5 10
33. K. Laliberte, C. Arneson, and R. Jeffs Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers J Cardiovasc Pharmacol 44 2004 209 214 (Pubitemid 38982164)
34. V.V. McLaughlin, R.L. Benza, and L.J. Rubin Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 2010 1915 1922
35. M. Gomberg-Maitland, and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur Respir J 31 2008 891 901
36. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804 (Pubitemid 34229650)
37. H. Olschewski, G. Simonneau, and N. Galie Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329 (Pubitemid 34815354)
38. V.V. McLaughlin, R.J. Oudiz, and A. Frost Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263 (Pubitemid 44924827)
39. A. Giaid, M. Yanagisawa, and D. Langleben Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 1993 1732 1739 (Pubitemid 23170122)
40. C. Rubens, R. Ewert, and M. Halank Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 120 2001 1562 1569 (Pubitemid 33078473)
41. R. Channick, G. Simonneau, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123 (Pubitemid 32971843)
42. L. Rubin, D. Badesch, and R. Barst Bosentan therapy for pulmonary arterial hypertension N Eng J Med 346 2002 896 903 (Pubitemid 34984638)
43. S. Provencher, O. Sitbon, and M. Humbert Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J 27 2006 589 595
44. M. Packer, J. McMurray, and B.M. Massie Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study J Card Fail 11 2005 12 20 (Pubitemid 40215308)
45. J.R. Teerlink Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 8 2002 124 127 (Pubitemid 34857276)
46. H. Vatter, M. Zimmermann, and C. Jung Effect of the novel endothelin (A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery Clin Sci (Lond) 103 Suppl 48 2002 408S 413S (Pubitemid 35007200)
47. N. Galie, H. Olschewski, and R.J. Oudiz Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
48. M.D. McGoon, A.E. Frost, and R.J. Oudiz Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities Chest 135 2009 122 129
49. J. Nagendran, S.L. Archer, and D. Soliman Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 2007 238 248 (Pubitemid 47196559)
50. N. Galie, H.A. Ghofrani, and A. Torbicki Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157 (Pubitemid 41653106)
51. J. Carlsen, K. Kjeldsen, and J. Gerstoft Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension AIDS 16 2002 1568 1569 (Pubitemid 34804229)
52. F. Reichenberger, R. Voswinckel, and B. Enke Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Eur Respir J 30 2007 922 927 (Pubitemid 351194796)
53. H. Ghofrani, R. Wiedemann, and F. Rose Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial Lancet 360 2002 895 900 (Pubitemid 35283832)
54. L.S. De Santo, C. Mastroianni, and G. Romano Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients Transplant Proc 40 2008 2015 2018
55. M. Guazzi, M. Samaja, and R. Arena Long-term use of sildenafil in the therapeutic management of heart failure J Am Coll Cardiol 50 2007 2136 2144 (Pubitemid 350117342)
56. A. Kulkarni, T.P. Singh, and A. Sarnaik Sildenafil for pulmonary hypertension after heart transplantation J Heart Lung Transplant 23 2004 1441 1444 (Pubitemid 40018169)
57. G.D. Lewis, R. Shah, and K. Shahzad Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Circulation 116 2007 1555 1562 (Pubitemid 47511419)
58. National Heart L, and Blood Institute (NHLBI). Evaluating the effectiveness of Sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study). In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. NLM identifier: NCT00763867: http://clinicaltrials.gov/ct2/show/NCT00763867; 2011 Apr 20.
59. N. Galie, B.H. Brundage, and H.A. Ghofrani Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
60. M.M. Hoeper, I. Markevych, and E. Spiekerkoetter Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur Respir J 26 2005 858 863 (Pubitemid 41632043)
61. G. Simonneau, L.J. Rubin, and N. Galie Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
62. M. Humbert, R.J. Barst, and I.M. Robbins Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353 359 (Pubitemid 39232254)
63. X.X. Wang, F.R. Zhang, and Y.P. Shang Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial J Am Coll Cardiol 49 2007 1566 1571
64. H.A. Ghofrani, M.M. Hoeper, and M. Halank Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Eur Respir J 36 2010 792 799
65. R.T. Schermuly, J.P. Stasch, and S.S. Pullamsetti Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Eur Respir J 32 2008 881 891
66. H.A. Ghofrani, N.W. Morrell, and M.M. Hoeper Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am J Respir Crit Care Med 182 2010 1171 1177
67. R.T. Schermuly, E. Dony, and H.A. Ghofrani Reversal of experimental pulmonary hypertension by PDGF inhibition J Clin Invest 115 2005 2811 2821 (Pubitemid 41434408)
68. M. Gomberg-Maitland, M.L. Maitland, and R.J. Barst A dosing/cross- development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension Clin Pharmacol Ther 87 2010 303 310
69. L. Moreno-Vinasco, M. Gomberg-Maitland, and M.L. Maitland Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension Physiol Genomics 33 2008 278 291 (Pubitemid 351629535)
70. M.R. MacLean Pulmonary hypertension and the serotonin hypothesis: where are we now? Int J Clin Pract Suppl 2007 27 31 (Pubitemid 47174380)
71. M.R. MacLean, G.A. Deuchar, and M.N. Hicks Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension Circulation 109 2004 2150 2155 (Pubitemid 38620226)
72. R. Dumitrascu, C. Kulcke, and M. Konigshoff Terguride ameliorates monocrotaline induced pulmonary hypertension in rats Eur Respir J 37 2011 1104 1118
73. B. Sztrymf, R. Souza, and L. Bertoletti Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension Eur Respir J 35 2010 1286 1293
74. S.A. van Wolferen, J.T. Marcus, and N. Westerhof Right coronary artery flow impairment in patients with pulmonary hypertension Eur Heart J 29 2008 120 127
75. R.T. Zamanian, F. Haddad, and R.L. Doyle Management strategies for patients with pulmonary hypertension in the intensive care unit Crit Care Med 35 2007 2037 2050 (Pubitemid 47326439)
76. F. Kerbaul, B. Rondelet, and S. Motte Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure Crit Care Med 32 2004 1035 1040 (Pubitemid 38471527)
77. S. Rich, S. Gubin, and K. Hart The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension Chest 98 1990 1102 1106 (Pubitemid 20381270)
78. A.M. Keogh, E. Mayer, and R.L. Benza Interventional and surgical modalities of treatment in pulmonary hypertension J Am Coll Cardiol 54 2009 S67 S77
79. N.S. Hill Pulmonary hypertension therapy 2006 Summit Communications, LLC Armonk (NY)
80. L.C. Price, S.J. Wort, and S.J. Finney Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review Crit Care 14 2010 R169